In the well-studied example of colorectal cancer, monotherapy targeting the epidermal growth factor receptor (EGFR) inevitably resulted in the expansion of KRAS mutant subpopulations that drive patient relapse [9, 10, 14]. The gene discussed is KRAS; the disease is colorectal cancer.